Neos Therapeutics collected commitments from investors including CMEA Capital, Burrill Life Sciences Capital Fund III and Crabtree Partners.
The company has already completed a commercialisation of an anti-cough and cold product, and is working on other orally disintegrating tablets and controlled-release liquid products.
Neos CEO Vipin Garg said, “We are very pleased that Neos’ progress has allowed us to attract strong support from our investors.
“This places the Company in an excellent financial position to execute our strategy of bringing novel products based on the Neos proprietary technologies to market.
“These technologies are currently being utilized to develop three ADHD products, which will advance significantly in the next 12-15 months.”
Copyright © 2014 AltAssets